The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Abstract
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-refractory tumours 1,2. We are testing melanoma FixVac (BNT111)-an intravenously administered liposomal RNA (RNA-LPX) vaccine, which targets four non-mutated, tumour-associated antigens that are prevalent in melanoma-in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT trial, ClinicalTrials.gov identifier NCT02410733). We report here data from an exploratory interim analysis that show that melanoma FixVac, alone or in combination with blockade of the checkpoint inhibitor PD1, mediates durable objective responses in checkpoint-inhibitor (CPI)-experienced patients with unresectable melanoma. Clinical responses are accompanied by the induction of strong CD4+ and CD8+ T cell immunity against the vaccine antigens. The antigen-specific cytotoxic T-cell responses in some responders reach magnitudes typically reported for adoptive T-cell therapy, and are durable. Our findings indicate that RNA-LPX vaccination is a potent immunotherapy in patients with CPI-experienced melanoma, and suggest the general utility of non-mutant shared tumour antigens as targets for cancer vaccination.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical trials of mRNA-based immunotherapeutics encoding unmutated full-length TAAs in checkpoint inhibitor-treated melanoma [18] and individualised mRNA-based immunotherapeutics encoding patient-specific mutated tumour neoantigens in pancreatic and lung cancer [19, 20] have shown encouraging results.”
From Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma (2025) · cites this paper as [18]
In the citing paper
“Previous studies have demonstrated that the use of BNT111 alone or in combination with PD-1 antibody can activate tumor antigen-specific CD4+ and CD8+ T cells and elicit durable immune responses.345,350–352”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [345]
In the citing paper
“For example, FixVac, which was developed based on the RNA-LPX formulation, is a systemic mRNA vaccine encoding four non-mutated antigens of melanoma200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“After the eighth immunization, more than 75% of patients generated immune responses against at least one tumour-associated antigen, and CD8+ T cells played a major role in high-magnitude T cell responses200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“Moreover, a combination of FixVac/anti-programmed cell death protein 1 (PD1) antibody augmented the antitumour effect of FixVac, resulting in a >35% tumour regression rate in immune checkpoint inhibitor-experienced patients200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
In the citing paper
“The interim analysis from the phase I trial (NCT02410733) showed that the metabolic activity of the spleen increased post the sixth immunization, indicating targeted delivery of FixVac and activation of resident immune cells200.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [200]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationMiXCR: software for comprehensive adaptive immunity profiling
Bolotin, D. A., Poslavskii, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,730
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A. A., Chen, Y., & Old, L. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1669 · Cited by 1,587
Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0737 · Cited by 1,388
Cited by
Sorted by citations
Items 701–800 of 1,000
Yin, F., Chao, M., Chen, J., Yao, Y., He, M., Wang, Q., Cheng, W., Cai, Y., Wang, Z., & Xiang, Y. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c04634 · Cited by 4
RNA vaccines for cancer: revolutionizing immunization strategies
Huang, D., Zhang, J., Zeng, X., Zhang, Y., & Song, E. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.09.003 · Cited by 4
A tumor-selective mRNA system enables precision cancer treatment
Żak, M. M., Yoo, J., Utrero‐Rico, A., Walter, W., Mainkar, G., Adjmi, M., Kurian, A. A., Rahaman, A., Lozano‐Ojalvo, D., Ochando, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.11.015 · Cited by 4
Development of mRNA Cancer Vaccines: Delivery Strategies and Immunogenicity Optimization
Ali, A. (2025) · Current Medical Science · doi:10.1007/s11596-025-00127-y · Cited by 4
mRNA Vaccines in Melanoma Immunotherapy—A Narrative Review
Plewa, P., Ćmil, M., Lewandowski, F., Poniewierska-Baran, A., & Pawlik, A. (2026) · Cells · doi:10.3390/cells15030298 · Cited by 4
Capturing and Tracking Clonal T-cell Response to Cancer Neoantigens
Shagina, I. A., Nakonechnaya, T. O., Izosimova, A. V., Shabalkina, A. V., Yuzhakova, D. V., Skatova, V. D., Lupyr, K. R., Muftakhutdinov, I., Izraelson, M., Davydov, A. N., et al. (2026) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-1216 · Cited by 4
Advances in predicting T cell epitope recognition for cancer immunotherapy
Gfeller, D., Racle, J., Harari, A., & Croce, G. (2026) · Nature Cancer · doi:10.1038/s43018-026-01144-z · Cited by 5
Cyboran-Mikołajczyk, S., Sareło, P., Pasławski, R., Pasławska, U., Przybyło, M., Nowak, K., Płóciennik, M., Podbielska, H., Kopaczyńska, M., & Wawrzyńska, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041710 · Cited by 4
Vegetable‐derived indole enhances the melanoma‐treating efficacy of chemotherapeutics
Zhou, B., Liu, D., Qian, J. C., & Tan, R. X. (2022) · Phytotherapy Research · doi:10.1002/ptr.7565 · Cited by 4
Noordam, L., de Beijer, M. T. A., Mancham, S., Vogler, I., Boor, P. P. C., de Ruiter, V., Luijten, R. J., IJzermans, J. N. M., Şahin, U., Bruno, M. J., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2131096 · Cited by 4
Self-citationZainodini, N., Abolhasani, M., Mohsenzadegan, M., Farajollahi, M. M., & Rismani, E. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05694-6 · Cited by 4
Bai, L., Chen, X., Li, C., Zhou, H., Li, Y., Xiao, J., Zhang, F., Cheng, H., & Zhou, M. (2024) · Drug Delivery · doi:10.1080/10717544.2024.2427138 · Cited by 4
Kim, E.-H., Wahl, K., Guelfi, E., & Lee, D. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.046 · Cited by 5
mRNA Technology in Modern Medicine: Review and Future Prospects
Silva, H. M. (2025) · Clinical and Molecular Epidemiology · doi:10.53964/cme.2025001 · Cited by 4
Izosimova, A. V., Yuzhakova, D. V., Skatova, V. D., Volchkova, L. N., Загайнова, Е. В., Chudakov, D. M., & Sharonov, G. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189859 · Cited by 4
James, C. A., Ronning, P., Cullinan, D. R., Cotto, K. C., Barnell, E. K., Campbell, K. M., Skidmore, Z. L., Sanford, D. E., Goedegebuure, S. P., Gillanders, W. E., et al. (2021) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0029 · Cited by 4
D’Anniballe, V. M., Huang, M.-N., Lueck, B. D., Nicholson, L. T., McFatridge, I., & Gunn, M. D. (2023) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000487 · Cited by 4
Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)
Julve, M., Kennedy, O., Frampton, A. E., Bagwan, I., & Lythgoe, M. P. (2023) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-209053 · Cited by 4
Advances, opportunities and challenges in developing therapeutic cancer vaccines
Duan, Z., Yang, D., Yuan, P., Dai, X., Chen, G., & Wu, D. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104198 · Cited by 4
Zhang, Y., Chen, Y., Lu, L., Xie, X., Ren, H., Wu, L., Tan, L.-N., Xu, T., & Jin, Y. J. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673275752231219080500 · Cited by 4
Therapeutic tumor vaccines — a rising star to benefit cancer patients
Wei, Q., Fang, Z., Zhang, Z., & Zhang, T. (2021) · WArtificial Intelligence in Cancer · doi:10.35713/aic.v2.i3.25 · Cited by 4
Reports of New and Recurrent Keratitis following mRNA-based COVID-19 Vaccination
Shah, P. P., Glidai, Y., Braunstein, R. E., Gorski, M. G., Lee, J., Anwar, F., Schrier, A., Winokur, J. A., & Steiner, A. (2022) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2022.2133730 · Cited by 4
Ninmer, E. K., Zhu, H., Chianese‐Bullock, K. A., & Slingluff, C. L. (2025) · International Journal of Cancer · doi:10.1002/ijc.70006 · Cited by 3
Zhou, R., Han, L., Wang, J., Ma, L., Zhang, T., Qi, T., Liu, M., Dong, Y., Zhang, W., & Cen, S. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3914 · Cited by 3
Ng, C. S. (2025) · Vaccines · doi:10.3390/vaccines13090911 · Cited by 3
Beg, M. M. A., Aslam, M., Ayaz, A., Akhtar, M. S., & Zaman, W. (2025) · Cells · doi:10.3390/cells14181453 · Cited by 4
Personalizing DNA Cancer Vaccines
Wu, A. A., Peng, K., Vukovich, M., Zhu, M., Lin, Y., Bagga, A., Wu, T. ‐., & Hung, C. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15100474 · Cited by 3
Immunomodulatory vaccine demonstrates therapeutic efficacy across cancer types
Han, T., Liu, G., Bao, C., Zong, J., Fei, C., Li, J., Xu, S., Ma, Q., & Qian, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-21924-4 · Cited by 3
Lipid Monolayers Adsorbing mRNA as Models for mRNA Enclosed in Lipid Nanoparticles for Transfection
Grava, M., Weber, K., Reed, J., Weber, B., Shen, C. C., Haas, H., & Schneck, E. (2025) · Langmuir · doi:10.1021/acs.langmuir.5c04076 · Cited by 3
Self-citationCarbon dot-lipidoid nanocarriers for superiorly biocompatible nasal mRNA cancer vaccination
Kim, H., Jeong, H., Kim, Y. A., Kim, K. S., Yun, J.-W., Li, F., Ling, D., & Na, K. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03844-7 · Cited by 3
Chen, H., Zhang, J., Huang, J., Wu, Z., Tang, L., Tian, Y., Gao, S., Huang, S., Cao, J., Chen, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07470-7 · Cited by 3
Technological advances in mRNA delivery and engineering for therapeutic cancer vaccines
Uchida, S. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf199 · Cited by 4
CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity
Hwang, B.-J., Crosby, E. J., Severson, D. T., Trotter, T. N., McBane, J., Tsao, L.-C., Wang, T., Liu, C.-X., Yang, X., Lei, G., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adz2294 · Cited by 3
mRNA Vaccines for Cancer Treatment
Torphy, R. J., Balachandran, V., & Soares, K. C. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.006 · Cited by 3
Therapeutic targeting of the HPV E7 oncoprotein: Current advances and emerging strategies
Gholami, S., Aghbash, P. S., Ravanlo, Z. Z., Rahimi, S. B., & Baghi, H. B. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116193 · Cited by 4
Fredericq, L., Hamouda, A. E. I., Zhong, Z., Ginderachter, J. A. V., Geest, B. G. D., & Laoui, D. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114799 · Cited by 3
Miyake-Stoner, S. J., Maine, C. J., Chou, A. C., Dailey, G. P., Spasova, D. S., Domingo, C. C., Sparks, J., Picarda, G. G. A., Lyerly, H. K., Crosby, E. J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.026 · Cited by 3
Kong, X., Cheng, R., Zhang, W., Lu, Y., Kan, Y., Fang, Y., Gao, J., Wang, J., & Hwang, K. C. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101392 · Cited by 4
Zeng, L. L., Shen, Q., Wei, L., Jiang, M. J., Liao, J., Ren, Y., Zhang, Z., Fan, H., Cao, X., Chen, J., et al. (2026) · Advanced Materials · doi:10.1002/adma.202520594 · Cited by 3
Qiu, F., Sun, Y., & Lim, D. W.-T. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102831 · Cited by 3
Polypeptide-engineered lipid nanoparticles for mRNA delivery with limited immunogenicity
Zeng, J., Zhang, Y., Zhao, G., Seow, B. Y. L., Balakrishnan, N., Goh, J. H., & Yang, Y. Y. (2026) · Nature Communications · doi:10.1038/s41467-026-73698-6 · Cited by 3
Chen, P., Chang, W.-C., Jhou, H., Chen, H., Kao, L., Hsieh, T. Y.-J., Dai, M., & Lee, C. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014726 · Cited by 3
Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms
Unuofin, J. O., Adefisan, A. O., Paimo, O. K., Maphetu, N., & Lebelo, S. L. (2026) · Molecules · doi:10.3390/molecules31142551 · Cited by 3
Melanoma - Standard of Care, Challenges, and Updates in Clinical Research
Maciá, S., & Castañón, E. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100843 · Cited by 3
Manco, R., D’Apice, L., Trovato, M., Lione, L., Salvatori, E., Pinto, E., Compagnone, M., Aurisicchio, L., De Berardinis, P., & Sartorius, R. (2023) · Viruses · doi:10.3390/v15030672 · Cited by 3
Burn, O. K., Dasyam, N., & Hermans, I. F. (2023) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2023049407 · Cited by 3
Fantini, M. C., Tsang, K. Y., & Arlen, P. M. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2397011 · Cited by 4
Pather, S., Charpentier, N., van den Ouweland, F., Rizzi, R., Finlayson, A., Salisch, N. C., Muik, A., Lindemann, C., Khanim, R., Abdul-Jawad, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126165 · Cited by 3
Marginal-zone B cells as promising targets of an mRNA-loaded, lipid-nanoparticle cancer vaccine
Suzuki, Y., Yakuwa, M., Sato, M., Samaridou, E., Beck‐Broichsitter, M., Maeki, M., Tokeshi, M., Yamada, Y., Harashima, H., & Sato, Y. (2025) · Next Nanotechnology · doi:10.1016/j.nxnano.2025.100154 · Cited by 3
Immunomodulatory nanoplatforms with multiple mechanisms of action in cancer treatment
Villa, R., Shiau, Y., Mahri, S., Racacho, K. J., Tang, M., Zong, Q., Ruiz, D., Kim, J., & Li, Y. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2500906 · Cited by 3
Pioneering next-generation mRNA therapeutics through molecular engineering and delivery optimization
Qi, L., Li, Z., Feng, Z., Liu, J., & Chen, X. S. (2025) · Materials Today · doi:10.1016/j.mattod.2025.08.023 · Cited by 3
RNA Vaccines: The Evolution, Applications, and the Challenges Ahead
Banerji, I., Bhattacharjee, S., Mukherjee, K., & Bhattacharyya, S. N. (2023) · Springer eBooks · doi:10.1007/978-981-19-8520-1_10 · Cited by 3
Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes
Bowen, C. M., Sinha, K. M., & Vilar, E. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1770383 · Cited by 3
Tumor metabolic crosstalk and immunotherapy
Zhang, Y., Nie, Y., Liu, X., Wan, X., Shi, Y., Zhang, K., Wu, P., & He, J. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03304-4 · Cited by 3
Federico, M. (2023) · Vaccines · doi:10.3390/vaccines11121847 · Cited by 3
Recent applications of RNA therapeutic in clinics
Thi, H. T. H., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.015 · Cited by 3
Vaccines and Oncolytic Virus for the Treatment of Lung Cancer
Dhar, A. K., Palei, N. N., & Kandula, D. R. (2024) · Springer eBooks · doi:10.1007/978-981-99-7141-1_12 · Cited by 3
Advances in Adjuvant and Neoadjuvant Therapy for Melanoma
Sierra-Davidson, K., & Boland, G. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.007 · Cited by 3
Into the Future: Fighting Melanoma with Immunity
Corica, D. A., Bell, S. D., Miller, P. J., Kasperbauer, D. T., Lawler, N. J., Wakefield, M. R., & Fang, Y. (2024) · Cancers · doi:10.3390/cancers16234002 · Cited by 3
SARS-CoV-2 vaccines, where do we stand?
Fischer, A. (2021) · Comptes Rendus Biologies · doi:10.5802/crbiol.35 · Cited by 3
Reinvigorating therapeutic cancer vaccines
Robles-Oteíza, C., & Wu, C. J. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102176 · Cited by 3
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
Timon-David, É., Perez, C., & Rodallec, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112326 · Cited by 3
Combined Application of Nanotechnology and Multiple Therapies with Tumor Immune Checkpoints
Yu, Z., Sun, Y., Sun, T., & Wang, T. (2020) · ChemistrySelect · doi:10.1002/slct.202004070 · Cited by 3
Innate and adaptive immunity in cancer
Doshi, A. S., & Asrani, K. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823397-9.00025-9 · Cited by 4
Drug-Loaded Liposomal Spherical Nucleic Acid as an Effective Cancer NanovaccinePreprint
Deng, B., Bing, M., Ma, Y., Cao, P., Leng, X., Huang, P., Ji, T., Lu, X., & Liu, L. (2021) · Research Square · doi:10.21203/rs.3.rs-1074689/v1 · Cited by 3
Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients
González‐Cao, M., & Rosell, R. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-55 · Cited by 3
LINE-1 ORF1p is a shared and immunogenic antigen in cancerPreprint
McKerrow, W., Snyder, M., Chu, C., Kelly, D., Keilhack, H., & Diao, L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.11.659092 · Cited by 3
Programmable Aptamer-Embedded Circular RNAs for Targeted Antigen-Presenting Cells ImmunotherapyPreprint
Zhang, Y., Wang, W., Qian, X., Chen, J., Ding, D., Gan, S., Yi, W., Li, Y., Deng, Y., Chen, Z., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.28.679023 · Cited by 3
Opportunity knocking: shared tumor-associated antigen vaccines against global cancer pandemic
Finn, O. J. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013130 · Cited by 3
Immunotherapy for Cutaneous Melanoma
Soleymanitabar, A., Keshavarz‐Fathi, M., Hargadon, K. M., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_237-1 · Cited by 2
RNA therapeutics: Molecular mechanisms, and potential clinical translations
Nguyen, T. T., Thi, Y.-V. N., & Chu, D. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.012 · Cited by 2
Meulewaeter, S., Velder, M. D., Reckelbus, D., Mwangi, K., Ehouarne, T., Aernout, I., Engelen, Y., Halimi, F., herteryck, I. V., Bels, L. D., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101493 · Cited by 3
Volkmar, M., Hoser, D., Lauenstein, C., Rebmann, J., Hotz‐Wagenblatt, A., Rieger, J., Poschke, I. C., Becker, J. P., Riemer, A. B., Sprick, M. R., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011802 · Cited by 2
Development of therapeutic cancer vaccines based on cancer immunity cycle
Zhang, J., Zheng, Y., Xu, L., Gao, J., Ou, Z., Zhu, M., & Wang, W. (2025) · Frontiers of Medicine · doi:10.1007/s11684-025-1134-6 · Cited by 2
Mucosal and transdermal delivery strategies for mRNA: Transforming the clinical applications
Wang, L., & Deng, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114221 · Cited by 2
Recent advances in gene delivery for melanocyte-associated disorders
Chhibber, T., Deacon, D. C., Ghandehari, H., & Judson‐Torres, R. L. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115703 · Cited by 3
Jiang, J., Li, L., Yu, Z., Wang, K., Ma, J., Dong, L., Guo, Z., Wang, L., Zhang, H., Xu, L., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104981 · Cited by 2
RNA-based cancer vaccines: mechanisms, clinical progress, and translational challenges
Al‐Kabariti, A. Y., Kadhim, M. A., Mousa, H. M., Jyothi, S. R., Nayak, P. P., Janney, J. B., Singh, G., & Chauhan, A. S. (2025) · Immunologic Research · doi:10.1007/s12026-025-09725-3 · Cited by 2
Gan, C. P., Kok, S. Y., Lee, B. K. B., Zulaziz, N., Cheong, S. C., Savelyeva, N., & Lim, K. P. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07418-x · Cited by 2
Lu, N., Han, J., Dong, L., Li, T., Margonis, G. A., Wang, J. J., Cao, H., Sun, Y., Wang, W., & Lin, C. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07287-4 · Cited by 2
Qiao, N., Chen, J., Liu, Y., Chen, Z. J., & Chen, S. J. (2026) · MedScience · doi:10.1007/s11684-026-1210-6 · Cited by 3
Biomineralized nanoemulsion delivers mRNA for potent cancer immunotherapy
Xu, Y., Tang, X., Guo, Z., Wang, Y., He, C., Wei, H., Xue, Y., Ou, Y., Ye, L., Zhao, Y., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114889 · Cited by 2
Recent advances in LNP-mRNA vaccines
Redenti, B. J., Zhong, Y., Yu, C., & Dong, Y. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115675 · Cited by 3
Healthy donor T cell receptors expand functional neoantigen recognition beyond patient vaccination
Teo, H. K., Han, S., Manoharan, T., Ren, Y., Cheng, C. Z. M., Loo, S. C., Lin, Z., Li, J., Wang, W.-W., Koo, S., et al. (2026) · Science Advances · doi:10.1126/sciadv.adz1156 · Cited by 2
Neoantigen-based T cell vaccines design strategies, therapeutic barriers, and clinical advances
Shi, J., Wang, J., 罗红梅, Zhao, Q., Yao, Z., Wu, G., Li, Z., Wang, H., Chen, G. D., & Wu, D. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128659 · Cited by 2
RNA-based cancer immunotherapy: Harnessing the power of RNA nanoparticles for melanoma treatment
Liu, X. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156512 · Cited by 2
Nanobiotechnology for dendritic cell-based cancer immunotherapy
Li, R. H., Yi, W., Qian, X., Hu, S., Shen, H., Yan, D., & Li, Y. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100485 · Cited by 2
Persico, I., Doro, M. G., Frogheri, L., Sini, M. C., Maestrale, G. B., Manca, A., Mallardo, D., Ascierto, P. A., & Palmieri, G. (2026) · Cells · doi:10.3390/cells15110986 · Cited by 2
Song, A., Zhang, Y., Ji, Y., Yuan, H., Ren, J., & Qu, X. (2026) · Nature Communications · doi:10.1038/s41467-026-74550-7 · Cited by 2
Younis, M. A., Sato, Y., Elewa, Y. H. A., & Harashima, H. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115172 · Cited by 2
Critical chemistry manufacturing and controls considerations for mRNA lipid nanoparticle translation
Liu, L., Wang, Y., Gao, H., Ruan, J., Lu, W., Liu, T., Li, X., Zhang, G., & Xiao, Y. (2026) · Discover Nano · doi:10.1186/s11671-026-04864-4 · Cited by 3
Yang, K., Hua, B., Qi, S., Bai, B., Yu, C., Huang, F., & Yu, G. (2022) · Angewandte Chemie · doi:10.1002/ange.202213572 · Cited by 2
Bafleh, W. S., Abdulsamad, H. M. R., Al-Qaraghuli, S. M., Khatib, R. Y. E., Elbahrawi, R. T., Abdukadir, A. M., Alsawae, S. M., Dimassi, Z., Hamdan, H., & Kashir, J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1198848 · Cited by 2
Zhang, L., Yang, S., Chen, H., Xue, C.-E., Wang, T.-E., Chen, S., Xu, X., Ma, S., Yu, M., Guo, T., et al. (2023) · PubMed Central · Cited by 2
Progress in mRNA cancer vaccine research, current limitations, application and future
Zeng, X. (2023) · Theoretical and Natural Science · doi:10.54254/2753-8818/20/20230742 · Cited by 2
Functionalized lipoplexes and polyplexes for cancer therapy
Chhikara, N., Singh, J., Sharma, A., Sood, A., & Kumar, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15518-5.00006-9 · Cited by 2
Optimal Neoantigen Cancer Vaccines Target CD8+ and CD4+ T Cells with Multiple Antigens
Slingluff, C. L. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0165 · Cited by 2
Targeted Drug Delivery for Cancer Therapy Using Functionalized Nanocarrier
Ogawa, K., Tagami, T., & Ozeki, T. (2024) · Nanomedicine and nanotoxicology · doi:10.1007/978-981-97-5288-1_3 · Cited by 2
Antitumor mRNA vaccines based on neoantigens
Starostina, E. V., Nizolenko, L. F., Карпенко, Л. И., & Ilyichev, A. A. (2025) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2024-23-6-149-158 · Cited by 2
Nisar, M. F., Yan, T., Cai, Y., & Wan, C. C. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10468-8 · Cited by 2
Metadata
- Authors
- Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H., Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitkreuz, A., Tolliver, C., Caspar, J., Quinkhardt, J., Hebich, L., Stein, M., Hohberger, A., Vogler, I., Liebig, I., Renken, S., Sikorski, J., Leierer, M., Müller, V., Mitzel-Rink, H., Miederer, M., Huber, C., Grabbe, S., Utikal, J., Pinter, A., Kaufmann, R., Hassel, J. C., Loquai, C., & Türeci, Ö.
- Affiliations
- BioNTech (Germany) (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- German Cancer Research Center (DE)
- University Hospital Frankfurt (DE)
- ORCID
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 585
- Issue
- 7823
- Pages
- 107-112
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3046115489
- Cited by
- 1,052
- References
- 36
- Citations by year
- 2026: 140 · 2025: 204 · 2024: 191 · 2023: 190 · 2022: 174 · 2021: 131 · 2020: 21
- FWCI
- 44.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- RNA vaccines, melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, tumor-associated antigens, cancer immunotherapy, CD4+ T cells, CD8+ T cells, cytotoxic T lymphocyte response
- MeSH terms
- Antigens, Neoplasm, Antineoplastic Agents, Combined Modality Therapy, Humans, Melanoma, Neoplasm Staging, RNA, Neoplasm, T-Lymphocytes, T-Lymphocytes, Cytotoxic, Vaccination, Cancer Vaccines, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
